Winning Stock Forecast: Omeros Corporation Stock (NASDAQ: OMER) Revitalizes Your Portfolio With 70.31% In 14 Days

Winning Stock Forecast

“We believe that we now have clear paths to accelerated approval for OMS721 in both stem-cell TMA and IgA nephropathy. With breakthrough therapy designations in both of these indications, we look forward to continuing to work closely with FDA and, for stem-cell TMA, we have initiated preparations for a BLA submission”

– Gregory A. Demopulos, M.D., Chairman and CEO of Omeros

Over the 14 days period from May 1st to May 15th, 2018 OMER stock price experienced steep price rise of more than 70%. Taking into account the overall OMER stock performance indicators for the last quarter, it is reasonable to suggest that this is the consequence of the company’s results achieved in 1Q 2018. Based on the press release on May 10, 2018 the following highlights are important to analyse:

  • 1Q 2018 total and OMIDRIA® revenues were $1.6 million, compared to $12.3 million in 1Q 2017; the decrease is the result of the scheduled expiration of OMIDRIA pass-through reimbursement status on January 1, 2018
  • Net loss in 1Q 2018 was $30.1 million, or $0.62 per share. Non-cash expenses for 1Q 2018 were $4.3 million, or $0.09 per share
  • At March 31, 2018, the company had cash, cash equivalents and short-term investments available for operations of $72.8 million. An additional $45.0 million available under the company’s existing credit facility is expected to fund on May 18, 2018

The above highlights could not pass unseen by the market and investors observed OMER stock growth of 70.31% during the above-mentioned period. The below chart illustrates this:

At the same time, the analyst community mostly took buy to strong buy positions on OMER stock over the last 4 months and indicating the average expected price of $36.20 being 79% more than the actual Omeros Corporation stock price. Also, we could see slightly increasing number of analysts who took strong buy position over the last months:

[Source: Yahoo Finance]

On May 1, 2018, I Know First issued a bullish 14 days forecast for Omeros Corporation (NASDAQ: OMER). The forecast illustrated a signal of 9.79 and a predictability of 0.14. In accordance with the forecast, OMER stock returned 70.31% over this period, highlighting the accuracy of the prediction produced by the I Know First algorithm.

Current I Know First subscribers received this bullish OMER forecast on May 1, 2018.

To subscribe today click here.

Best Biotech Stocks

How to interpret this diagram

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. Its clinical programs include OMS721 that is in Phase III clinical trial for treating immunoglobulin A (IgA) nephropathy, hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA), and atypical hemolytic uremic syndrome (aHUS); and in Phase II clinical trial to treat IgA nephropathy, membranous nephropathy, lupus nephritis, and complement component glomerulopathy. The company’s clinical programs also consists of OMS824, which is in Phase II clinical trial for treating Huntington’s diseases and schizophrenia; and OMS405 that is in Phase II clinical trial to treat opioids, nicotine, and alcohol addiction. Its preclinical programs comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders; and OMS906 to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. The company’s preclinical programs also include MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HCT-TMA, and age-related macular degeneration; MASP-3-small-molecule inhibitors used for the treatment of PNH and other alternative pathway disorders; G protein-coupled receptor (GPCR) platform, including GPR174 and other Class A orphan GPCRS for treating CNS, metabolic, CV, oncologic, musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal and other disorders. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.

Disclaimer

Before making any trading decisions, consult the latest forecast as the algorithm updates predictions daily. You can use the algorithm for intra-day trading. The predictability tends to become stronger with forecasts over longer time-horizons such as the 1-month, 3-month and 1-year forecasts.